Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure

BACKGROUND: Asciminib is an allosteric inhibitor that binds a myristoyl site of the BCR-ABL1 protein, locking BCR-ABL1 into an inactive conformation through a mechanism distinct from those for all other ABL kinase inhibitors. Asciminib targets both native and mutated BCR-ABL1, including the gatekeep...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:N Engl J Med
Prif Awduron: Hughes, T.P., Mauro, M.J., Cortes, J.E., Minami, H., Rea, D., DeAngelo, D.J., Breccia, M., Goh, Y.-T., Talpaz, M., Hochhaus, A., le Coutre, P., Ottmann, O., Heinrich, M.C., Steegmann, J.L., Deininger, M.W.N., Janssen, J.J.W.M., Mahon, F.-X., Minami, Y., Yeung, D., Ross, D.M., Tallman, M.S., Park, J.H., Druker, B.J., Hynds, D., Duan, Y., Meille, C., Hourcade-Potelleret, F., Vanasse, K.G., Lang, F., Kim, D.-W.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2019
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7724923/
https://ncbi.nlm.nih.gov/pubmed/31826340
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1902328
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg